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Coagulation Activity Is Increased in the Left 
Atrium of Patients With Mitral Stenos is~l  
I read the study by Yamamoto et al. (I) with immense interest. 
However, their conclusion of activation of the coagulation system in 
the left atrium even during anticoagulation may be incorrect. We do 
not know thc severity of pulmonary hypertension i the patients 
studied. Although the authors found no correlation of elevated 
fibrinopeptide A (FPA) levels with either chronic atrial fibrillation or 
severity of mitral stenosis, no attempt at correlation with severity of 
pulmonary hypertension was made. There is evidence to suggest 
activation of the coagulation system in pulmonary hypertension, both 
in primary (2) and seconda U pnlmona U hypertension (3), although 
controversy also exists (4). To my knowledge, no studies have been 
done to date on FPA or thrombin anti-thrombin III (TAT) activity and 
pulmonary hypertension secondary to mitral stenosis. The coaguhttion 
activation i  the present study suggests an activation in the pulmona~ 
circuit rather than the left atrium, contra U to the suggestion by the 
authors. If this hypothesis is correct, particularly if the FPA levels 
decrease after correction of mitra[ stcnosis, pulmona U hypertension 
with mitral stenosis may itself be a risk factor for coagulation. Hencc, 
there is an argument for early definitive therapy for mitral stenosis to 
better control or correct the coagulation abnormality. 
The TAT levels in the present study were not significantly clcvatcd 
in the left atrium, although they correlated with the FPA levels. This 
difference could have resulted from the influence of different blood 
sampling techniques. Significantly lower TAT levels are measured in 
blood samples taken from central cathcters than those with blot~d 
samples obtained from direct venipunctures (5). The TAT levels 
measured in the left atrium in the present study may thus be 
artifactually low, when the TAT levels are in fact significantly clcwtlcd 
in patients with mitral stcnosis. 
Congratulations for the wonderful study. 
MUMTAZ A. SIDDIQU1, MD. MR('P 
The Graduate ftov~ital 
Philadelphia. Penn.svk'ania 19144 
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Coagulation Activity Is Increased in the Left 
Atrium of Patients With Mitral Stenosis~l I  
We read with interest the reporl by Yamamoto et al. ( I ) on coagula- 
tion activity in patients with mitral stenosis. In this interesting study. 
various coagulation markers in 12 patients were compared with those 
15 normal subjects. 
Eleven of the 12 patients were in alrial fibrillation, but the heart 
rhythm of the normal control subjects was not stated (we assume that 
they were in sinus rhythm) (1). However, patients with atrial fibrilla- 
tion who are not receiving any antithrombotic herapy are known to 
demonstrate abnormalities in coagulation factors, consistent with a 
prothrombotic or hypercoagulable state, that may contribute to the 
high risk of stroke and thromboembolism in such patients. For 
example, patients with atrial fibrillation who are not receiving any 
antithrombotic herapy demonstrate an elevation in plasma levels of 
fibrinogen, fibrin D-dimer, von Willebrand factor antigen and beta- 
thromboglobulin compared with control subjects in sinus rhythm, and 
this finding is independent of any underlying structural heart disease 
(2-4). There was also no relation to left atrial size or ventricular 
function (3). 
In addition, all patients in the study by Yamamoto et al. (1) had 
received warfarin therapy for 3 months. The introduction of warfarin 
therapy normalizes certain markers of thrombogenesis, such as fibrin 
D-direct and beta-tbromboglobulin; although other markers, such as 
yon Willebrand factor antigen and fibrinogen, remain unchanged (3,4). 
It is therefore not surprising that Yamamoto et al. (1) found no 
significant differences in levels of D-dimer and beta-thromboglobulin 
betwecn their patients (taking warfarin) and control subjects and that 
von Willebrand factor antigen levels remained significantly elevated. A
better assessment of hypercoagulablc state in mitral stenosis would 
have been to compare patients with mitra[ stenosis in sinus rhythm 
(and not on any antithrombotic herapy) and matched healthy control 
subjects in sinus rhythm (who are also not receiving any therapy). 
However, whether such a study is feasible remains debatable because 
most patients with significant mitral stenosis hould be started on 
antithrombotic therapy, in view of the risk of developing atrial 
fibrillation and thromboembolism. 
GREGORY Y. H. LIP, MD, MBCHB, MRCP, DFM 
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Reply 
Wc very much appreciate the interest of Siddiqui n our recent study 
on coagulation activity in the left atrium of patients with mitral stcnosis 
(1). Siddiqui raises two issues with regard to our study. The first is 
the possibility of increased coagulability in the pulmonary circuit 
rather than in the left atrium of patients with mitral stenosis. We 
therefore ewtluated the correlation of elevated fibrinopeptide A 
(FPA) and thrombin-antithrombin III complex (TAT) levels in the 
left atrium of the patients in relation to the severity of pulmonary 
hypertension. However, the levels of these biochemical markers did 
not correlate well with the mean pulmonary artery pressure (FPA: 
r - 0.47, p 0.13: TAT: r - 0.41, p - 0.19). As pointed out by 
